IL1B and arthritic joint disease: <i>In vivo</i>, GHTFs treatment reduced clinical arthritis scores by over 40%, alleviated synovial hyperplasia, preserved collagen volume fraction, and lowered serum levels of TNF-α and IL-1β, demonstrating superior overall efficacy compared to AF and methotrexate (<i>P</i> >0.05).